MIMEDX GROUP INC (MDXG) Stock Fundamental Analysis
NASDAQ:MDXG - Nasdaq - US6024961012 - Common Stock - Currency: USD
MDXG gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 562 industry peers in the Biotechnology industry. MDXG is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. MDXG has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
MDXG had positive earnings in the past year.
In the past year MDXG had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: MDXG reported negative net income in multiple years.
In multiple years MDXG reported negative operating cash flow during the last 5 years.
1.2 Ratios
With an excellent Return On Assets value of 14.86%, MDXG belongs to the best of the industry, outperforming 96.98% of the companies in the same industry.
The Return On Equity of MDXG (19.82%) is better than 96.26% of its industry peers.
The Return On Invested Capital of MDXG (14.58%) is better than 96.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.86% | ||
| ROE | 19.82% | ||
| ROIC | 14.58% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MDXG's Profit Margin of 11.40% is amongst the best of the industry. MDXG outperforms 94.31% of its industry peers.
MDXG has a Operating Margin of 12.86%. This is amongst the best in the industry. MDXG outperforms 94.66% of its industry peers.
In the last couple of years the Operating Margin of MDXG has remained more or less at the same level.
MDXG has a Gross Margin of 81.94%. This is amongst the best in the industry. MDXG outperforms 85.23% of its industry peers.
In the last couple of years the Gross Margin of MDXG has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.86% | ||
| PM (TTM) | 11.4% | ||
| GM | 81.94% |
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MDXG is still creating some value.
Compared to 1 year ago, MDXG has more shares outstanding
Compared to 5 years ago, MDXG has more shares outstanding
The debt/assets ratio for MDXG has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 11.33 indicates that MDXG is not in any danger for bankruptcy at the moment.
MDXG has a better Altman-Z score (11.33) than 90.04% of its industry peers.
The Debt to FCF ratio of MDXG is 0.29, which is an excellent value as it means it would take MDXG, only 0.29 years of fcf income to pay off all of its debts.
MDXG has a Debt to FCF ratio of 0.29. This is amongst the best in the industry. MDXG outperforms 96.44% of its industry peers.
MDXG has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.09, MDXG is not doing good in the industry: 64.41% of the companies in the same industry are doing better.
Even though the debt/equity ratio score it not favorable for MDXG, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.29 | ||
| Altman-Z | 11.33 |
ROIC/WACC1.45
WACC10.03%
2.3 Liquidity
A Current Ratio of 4.70 indicates that MDXG has no problem at all paying its short term obligations.
MDXG has a Current ratio (4.70) which is comparable to the rest of the industry.
MDXG has a Quick Ratio of 4.13. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
MDXG has a Quick ratio (4.13) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.7 | ||
| Quick Ratio | 4.13 |
3. Growth
3.1 Past
MDXG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -37.78%.
MDXG shows a small growth in Revenue. In the last year, the Revenue has grown by 5.34%.
Measured over the past years, MDXG shows a small growth in Revenue. The Revenue has been growing by 3.11% on average per year.
EPS 1Y (TTM)-37.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
Revenue 1Y (TTM)5.34%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%4.13%
3.2 Future
MDXG is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 58.87% yearly.
Based on estimates for the next years, MDXG will show a quite strong growth in Revenue. The Revenue will grow by 12.54% on average per year.
EPS Next Y-3.28%
EPS Next 2Y14.46%
EPS Next 3Y58.87%
EPS Next 5YN/A
Revenue Next Year8.26%
Revenue Next 2Y9.83%
Revenue Next 3Y10.96%
Revenue Next 5Y12.54%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 25.89, MDXG can be considered very expensive at the moment.
Based on the Price/Earnings ratio, MDXG is valued cheaper than 94.66% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 24.83. MDXG is around the same levels.
Based on the Price/Forward Earnings ratio of 19.08, the valuation of MDXG can be described as rather expensive.
Based on the Price/Forward Earnings ratio, MDXG is valued cheaply inside the industry as 92.35% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of MDXG to the average of the S&P500 Index (20.94), we can say MDXG is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.89 | ||
| Fwd PE | 19.08 |
4.2 Price Multiples
MDXG's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MDXG is cheaper than 94.84% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, MDXG is valued cheaper than 96.26% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.55 | ||
| EV/EBITDA | 17.68 |
4.3 Compensation for Growth
MDXG has a very decent profitability rating, which may justify a higher PE ratio.
MDXG's earnings are expected to grow with 58.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.46%
EPS Next 3Y58.87%
5. Dividend
5.1 Amount
MDXG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
7.25
+0.2 (+2.84%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners70.4%
Inst Owner Change0.4%
Ins Owners2.22%
Ins Owner Change1.11%
Market Cap1.07B
Analysts81.82
Price Target12.24 (68.83%)
Short Float %3.35%
Short Ratio8.57
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.48%
Min EPS beat(2)-31.92%
Max EPS beat(2)6.95%
EPS beat(4)3
Avg EPS beat(4)9.74%
Min EPS beat(4)-31.92%
Max EPS beat(4)52.51%
EPS beat(8)7
Avg EPS beat(8)71.29%
EPS beat(12)9
Avg EPS beat(12)45.41%
EPS beat(16)12
Avg EPS beat(16)48.58%
Revenue beat(2)2
Avg Revenue beat(2)1.09%
Min Revenue beat(2)0.33%
Max Revenue beat(2)1.86%
Revenue beat(4)2
Avg Revenue beat(4)-0.5%
Min Revenue beat(4)-3.85%
Max Revenue beat(4)1.86%
Revenue beat(8)6
Avg Revenue beat(8)1.5%
Revenue beat(12)8
Avg Revenue beat(12)1.63%
Revenue beat(16)12
Avg Revenue beat(16)2.9%
PT rev (1m)-12.73%
PT rev (3m)-7.69%
EPS NQ rev (1m)-8%
EPS NQ rev (3m)-25.81%
EPS NY rev (1m)-0.9%
EPS NY rev (3m)-11.29%
Revenue NQ rev (1m)-2.57%
Revenue NQ rev (3m)-3.39%
Revenue NY rev (1m)-0.67%
Revenue NY rev (3m)-0.85%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.89 | ||
| Fwd PE | 19.08 | ||
| P/S | 3.03 | ||
| P/FCF | 16.55 | ||
| P/OCF | 16.31 | ||
| P/B | 5.27 | ||
| P/tB | 6.2 | ||
| EV/EBITDA | 17.68 |
EPS(TTM)0.28
EY3.86%
EPS(NY)0.38
Fwd EY5.24%
FCF(TTM)0.44
FCFY6.04%
OCF(TTM)0.44
OCFY6.13%
SpS2.39
BVpS1.38
TBVpS1.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.86% | ||
| ROE | 19.82% | ||
| ROCE | 19.89% | ||
| ROIC | 14.58% | ||
| ROICexc | 27.36% | ||
| ROICexgc | 36.54% | ||
| OM | 12.86% | ||
| PM (TTM) | 11.4% | ||
| GM | 81.94% | ||
| FCFM | 18.33% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-47.46%
ROICexc growth 3YN/A
ROICexc growth 5Y-21.46%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
F-Score5
Asset Turnover1.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.29 | ||
| Debt/EBITDA | 0.33 | ||
| Cap/Depr | 11.12% | ||
| Cap/Sales | 0.27% | ||
| Interest Coverage | 27.66 | ||
| Cash Conversion | 121.79% | ||
| Profit Quality | 160.71% | ||
| Current Ratio | 4.7 | ||
| Quick Ratio | 4.13 | ||
| Altman-Z | 11.33 |
F-Score5
WACC10.03%
ROIC/WACC1.45
Cap/Depr(3y)52.31%
Cap/Depr(5y)58.09%
Cap/Sales(3y)0.72%
Cap/Sales(5y)1.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-37.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
EPS Next Y-3.28%
EPS Next 2Y14.46%
EPS Next 3Y58.87%
EPS Next 5YN/A
Revenue 1Y (TTM)5.34%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%4.13%
Revenue Next Year8.26%
Revenue Next 2Y9.83%
Revenue Next 3Y10.96%
Revenue Next 5Y12.54%
EBIT growth 1Y-18.47%
EBIT growth 3YN/A
EBIT growth 5Y2.02%
EBIT Next Year27.87%
EBIT Next 3Y22.35%
EBIT Next 5YN/A
FCF growth 1Y533.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y659.04%
OCF growth 3YN/A
OCF growth 5YN/A